Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4387 - Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: phase III EPIC trial


09 Sep 2017


Poster display session


End-of-life Care;  Gastrointestinal Cancers


Emilie Hutt


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


E. Hutt1, A. Da silva2, D. Pannier1, E. Bogart3, F. El-Hajbi1, S. Villet2, S. Clisant4, M. Le Deley3, A. Adenis1

Author affiliations

  • 1 Medical Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 2 Palliative Care, Centre Oscar Lambret, 59020 - Lille/FR
  • 3 Biostatistics, Centre Oscar Lambret, 59020 - Lille/FR
  • 4 Clinical Research Unit, Centre Oscar Lambret, 59020 - Lille/FR


Abstract 4387


Palliative care (PC) has usually been offered at end-life stage, although the World Health Organization recommends providing PC as early as possible in the course of malignancies. Temel et al. (N Engl J Med 2010) have shown that early PC (EPC) provides a favorable effect on quality of life, as well as a surprising benefit on overall survival (OS) (secondary endpoint of this trial) over standard treatment to patients (pts) with metastatic lung cancer. Median OS of pts with metastatic upper gastrointestinal (upGI) cancers does not exceed 10-11 months, which is as poor as that reported with metastatic lung cancers. Whether or not OS benefit with EPC also applies to pts with metastatic upGI cancers is unknown. Demonstration of such benefit in these pts would lead to an earlier integration of PC in oncologic care.

Trial design

EPIC is a randomized phase III trial. It is aimed to estimate the OS benefit of EPC combined with standard oncologic care over standard oncology care only, in pts with metastatic upGI cancers who start 1st-line chemotherapy. Eligibility criteria also include ECOG PS ≤ 2, and life expectancy > 4 weeks. Main exclusion criteria include: locally advanced tumors, esogastric cancers with unknown or positive HER2 status, dysphagia, and jaundice. Treatments will be randomized in a 1:1 ratio; a minimization procedure will be used to balance pts according to center, PS (0-1 vs 2) and tumor location (esogastric/gastric, pancreas, and biliary tract). Pts will be recruited nationwide, in 17 university hospitals or cancer centers. OS will be used as a primary endpoint. The content of PC visits will be studied through a specific checklist. Patient-reported outcomes (quality of life, depression and anxiety) will be also investigated. Assuming an exponential distribution of survival time, 381 deaths are required to ensure an 80%-power for an absolute difference of 10% in one-year OS (40% vs 50.3%, HR = 0.75; logrank test two-sided alpha=5%), leading to a planned sample size of 480 pts enrolled over 3 years. The main analysis will be performed on the intention-to-treat dataset. Enrollment began on September 2016.

Clinical trial identification


Legal entity responsible for the study

Centre Oscar Lambret




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.